Clinical Trial

Alectinib in Neo-adjuvant Treatment of Stage III NSCLC

Study acronym: ALNEO
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 9, 2024 (before its estimated December 28, 2024 completion). Its status may not reflect the trial's current state.
Summary
Stage III NSCLC is a heterogeneous group of tumors with a wide spectrum of clinical presentations. Across this wide spectrum of heterogeneity, there is no single definitive therapeutic approach and the definition of the most effective treatment approach needs a multidisciplinary approach. In this trial we want to test in ALK positive stage III locally advanced NSCLC patients, the efficacy of Alectinib to induce tumor shrinkage when administered before surgery and to reduce the possibility of disease recurrence, with a limited risk of toxicity related, in long term administration after surgery.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2021-08-16; most recent amendment 2024-08-07.
Status change: Recruiting → Active, Not Recruiting 2024-08-07
Trial Details
NCT Number NCT05015010
Lead Sponsor Gruppo Oncologico Italiano di Ricerca Clinica
Conditions Non Small Cell Lung Cancer
Enrollment 33 participants
Start Date 2021-05-20
Primary Completion 2024-12-28 (estimated)
Study Completion 2026-12-28 (estimated)
Updated on ClinicalTrials.gov 2024-08-09